The lack of safe and efficient gene-delivery methods is a limiting obstacle to human gene
therapy. Synthetic gene-delivery agents, although safer than recombinant viruses, generally …

Gene therapy has long sought to treat disease by delivering therapeutic genes to diseased
cells. However, its widespread clinical use has faltered in the face of several challenges …

Abnormal folding of α-synuclein (α-syn) is thought to lead to neurodegeneration and the
characteristic symptoms of Lewy body disease (LBD). Since previous studies suggest that …

Gene-based therapeutics hold great promise for medical advancement and have been used
to treat various human diseases with mixed success. However, their therapeutic application …

Multiple convergent lines of evidence implicate both α-synuclein (encoded by SCNA) and
mitochondrial dysfunction in the pathogenesis of sporadic Parkinson's disease (PD) …

Parkinson's disease (PD) is a common chronic progressive neurodegenerative disorder in
elderly people. A consistent neurochemical abnormality in PD is degeneration of …

Gene therapy has been pursued in the past two decades for treatment of diseases
associated with defective gene expression. The insertion of a therapeutic gene into cells …

A number of neurodegenerative disorders may potentially be treated by the delivery of
therapeutic genes to neurons. Nonviral gene delivery systems, however, typically provide …

Parkinson's disease (PD) is an aging-associated neurodegenerative disorder with
progressive pathology involving the loss of midbrain dopaminergic neurons. Neurotrophic …

Gene therapy is an emerging therapeutic strategy for the cure or treatment of a spectrum of
genetic disorders. Nevertheless, advances in gene therapy are immensely reliant upon …